Litigation Details for Pedersen v. Geschwind (D. Maryland 2015)
✉ Email this page to a colleague
Pedersen v. Geschwind (D. Maryland 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-06-11 |
| Court | District Court, D. Maryland | Date Terminated | 2015-10-29 |
| Cause | 28:1331dj Fed. Question: Declaratory Judgment | Assigned To | James Kelleher Bredar |
| Jury Demand | Referred To | ||
| Patents | 8,119,116 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Pedersen v. Geschwind
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Pedersen v. Geschwind (D. Maryland 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-10-29 | 37 | treatment of liver cancer, while U.S. Patent No. 8,119,116 (“the ’116 patent”) is directed to the treatment …BrPA”). (ECF No. 12–3 at 27.) U.S. Patent No. 8,119,116 (“the ’116 patent”) claims methods of treating cancerous…explaining that patent inventorship—like patent infringement—is a unique question of patent law and that …-bromopyruvate (“3-BrPA”). U.S. Patent No. 7,547,673 (“the ’673 patent”) is directed to the treatment…both patents by assignment from the inventors, though JHU is nominal assignee of the ’673 patent. (ECF | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
